Quarterly Institutional Activity in OKYO

Shares Bought
Shares Sold
View Transactions

Top Institutions Holding OKYO

View all

Latest Institutional Activity in OKYO

Top Purchases

Q1 2023
Goldman Sachs Group Inc Shares Held: 19.8K ($20.2K)
Q1 2023
Concourse Financial Group Securities, Inc. Shares Held: 0 ($0)
Q4 2022
Ubs Group Ag Shares Held: 7.52K ($7.67K)
Q2 2022
Tower Research Capital LLC (Trc) Shares Held: 229 ($234)

Top Sells


About OKYO

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.


Insider Transactions at OKYO

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
570K Shares
From 1 Insiders
Other acquisition or disposition 570K shares
Sell / Disposition
0 Shares
From 0 Insiders

Track Institutional and Insider Activities on OKYO

Follow OKYO Pharma Ltd and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells OKYO shares.

Notify only if

Insider Trading

Get notified when an Okyo Pharma LTD insider buys or sells OKYO shares.

Notify only if

News

Receive news related to OKYO Pharma Ltd

Track Activities on OKYO